{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:10:30Z","timestamp":1784686230707,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.eururo.2007.08.053","type":"journal-article","created":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T07:24:06Z","timestamp":1188977046000},"page":"376-381","source":"Crossref","is-referenced-by-count":102,"title":["High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor"],"prefix":"10.1016","volume":"53","author":[{"given":"Damien","family":"Pouessel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2007.08.053_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.eururo.2006.01.016","article-title":"Understanding the importance of smart drugs in renal cell carcinoma","volume":"49","author":"Patard","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.08.053_bib2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1586\/14737140.6.12.1761","article-title":"Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel","volume":"6","author":"Pouessel","year":"2006","journal-title":"Exp Rev Anticancer Ther"},{"key":"10.1016\/j.eururo.2007.08.053_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2007.08.053_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa (IFN-\u03b1) in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2007.08.053_bib5","first-page":"930s","article-title":"A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma","volume":"24","author":"Hudes","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.eururo.2007.03.035","article-title":"Renal cell carcinoma guideline","volume":"51","author":"Ljungberg","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.08.053_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib8","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib9","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2007.08.053_bib10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2007.08.053_bib11","first-page":"222s","article-title":"Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC)","volume":"24","author":"Rini","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib12","first-page":"364s","article-title":"Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial","volume":"24","author":"Socinski","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib13","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2007.08.053_bib15","first-page":"237s","article-title":"Sunitinib in metastatic renal cell carcinoma: preliminary assessment of toxicity in an expanded access trial with subpopulation analysis","volume":"25","author":"Gore","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib16","first-page":"650s","article-title":"The Advanced Renal Cell Carcinoma Sorafenib expanded access trial: subset analysis of patients with brain metastases","volume":"25","author":"Henderson","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/01.nrl.0000178757.68551.26","article-title":"Intracerebral hemorrhage","volume":"11","author":"Badjatia","year":"2005","journal-title":"Neurologist"},{"key":"10.1016\/j.eururo.2007.08.053_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jocn.2004.12.012","article-title":"Primary intracerebral hemorrhage","volume":"13","author":"Sutherland","year":"2006","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.eururo.2007.08.053_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.jhh.1001647","article-title":"Blood pressure in acute intracerebral haemorrhage","volume":"18","author":"Rasool","year":"2004","journal-title":"J Hum Hyperten"},{"key":"10.1016\/j.eururo.2007.08.053_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nat Cancer Rev"},{"key":"10.1016\/j.eururo.2007.08.053_bib21","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1470-2045(01)00518-6","article-title":"The role of the coagulation system in tumour angiogenesis","volume":"2","author":"Nash","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.08.053_bib23","first-page":"246s","article-title":"Safety of VEGF-targeted tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and central nervous system metastases","volume":"25","author":"Unnithan","year":"2007","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807011360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807011360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T13:50:39Z","timestamp":1546609839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283807011360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0302283807011360"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2007.08.053","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}